As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

emmm201202168.reviewer_comments.pdfPDF document375KReview Process File
emmm201202168-sm-0002-SuppFigs-S1.pdfPDF document2931K

Figure S1. Evidence for an alternative Mybpc3 variant mRNA in wild-type mouse cardiac myocytes.

Figure S2. Evaluation of Var-4 Mybpc3 mRNA during mouse development.

Figure S3. Effect of 2OMePS-modified AONs on Mybpc3 mRNAs and cMyBP-C proteins in WT and KI cardiac.

Figure S4. Evaluation of the Mybpc3 mRNA species in wildtype cardiac myocytes.

Figure S5. Tissue distribution of GFP after systemic administration of AAV9 in a Mybpc3-targeted knock-in mouse.

Figure S6. Immunofluorescence analysis of cardiac sections after systemic administration of AAV9 in Mybpc3-targeted knock-in mice.

Figure S7. Variant-4 rescues the phenotype of Mybpc3-targeted KI mice in the heart in vivo.

Figure S8. Evaluation of AAV9 particles in ventricular tissue of KI injected mice.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.